Financial Performance - The company's revenue for Q1 2023 was ¥1,495,439,073.13, a decrease of 93.12% compared to ¥21,736,870,739.50 in the same period last year[3] - Net profit attributable to shareholders was ¥601,496,251.76, down 95.80% from ¥14,311,867,476.47 year-on-year[3] - The basic earnings per share decreased to ¥1.2772, a decline of 95.93% from ¥31.3920 in the previous year[3] - Total operating revenue for Q1 2023 was CNY 1,495,439,073.13, a significant decrease from CNY 21,736,870,739.50 in the same period last year[13] - Net profit for Q1 2023 was CNY 715,140,634.14, compared to CNY 15,257,942,841.81 in Q1 2022, indicating a substantial decline[14] - The total comprehensive income for the first quarter was CNY 454,029,305.09, compared to CNY 15,245,031,404.27 in the previous period[15] Assets and Liabilities - The total assets at the end of the reporting period were ¥22,127,092,267.00, an increase of 1.82% from ¥21,730,643,774.98 at the end of the previous year[3] - The company's total assets increased to CNY 22,127,092,267.00 from CNY 21,730,643,774.98 year-over-year[12] - Total liabilities decreased to CNY 1,547,470,889.80 from CNY 1,705,942,406.46 in the previous year[12] - The company's equity attributable to shareholders rose to CNY 20,003,813,439.49, up from CNY 19,554,218,225.76 year-over-year[12] Cash Flow - Cash flow from operating activities was ¥774,274,874.97, down 93.91% from ¥12,719,185,146.12 in the same period last year[3] - Net cash flow from operating activities was CNY 774,274,874.97, significantly lower than CNY 12,719,185,146.12 in the previous period[16] - The company reported a decrease in cash flow from operating activities, with cash inflows totaling CNY 1,589,084,110.25, down from CNY 17,833,437,850.37 in the previous period[16] - Cash inflow from investment activities totaled CNY 3,305,853,178.30, compared to CNY 219,398,566.33 in the previous period[17] - Net cash flow from investment activities was negative at CNY -732,707,257.50, compared to CNY -114,035,009.53 in the previous period[17] - The cash and cash equivalents at the end of the period stood at CNY 5,527,897,584.36, down from CNY 12,938,770,737.53 in the previous period[17] Expenses - Operating costs for Q1 2023 amounted to CNY 785,986,402.06, down from CNY 4,844,206,985.44 year-over-year[13] - The company reported a significant reduction in sales and management expenses, with sales expenses down 74.86% and management expenses down 46.32% compared to the previous year[6] - Research and development expenses for Q1 2023 were CNY 72,848,101.89, an increase from CNY 60,553,065.68 in the same quarter last year[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 149,933[8] - The largest shareholder, Shihezi Sanhe Equity Investment Partnership, holds 24.05% of the shares, totaling 116,544,519 shares[8] - The company does not have any preferred shareholders as per the report[9] - The company is unaware of any relationships or concerted actions among the top 10 shareholders[9] Investment Activities - Investment cash payments increased to ¥4,028,962,710.43, a rise of 1651.72% compared to ¥230,000,000.00 in the previous year[7] - The company experienced a 1401.24% increase in cash received from investment, totaling ¥3,190,121,655.58, compared to ¥212,498,566.33 last year[7] - The company reported an investment income of CNY 119,787,222.87, a recovery from a loss of CNY 1,919,799.05 in the previous year[14] Other Financial Metrics - The weighted average return on equity dropped to 3.02%, a decrease of 139.69% from 142.71% in the previous year[3] - Deferred tax assets increased to CNY 79,507,917.00 from CNY 52,521,826.08 year-over-year[12] - The company's cash and cash equivalents at the end of Q1 2023 amount to ¥5,562,835,995.14, an increase from ¥5,443,937,803.45 at the beginning of the year[10] - The total current assets are reported at ¥12,924,564,815.71, down from ¥13,194,977,225.32 at the beginning of the year[10] - The company's trading financial assets are valued at ¥6,115,301,829.58, compared to ¥6,044,046,377.99 at the start of the year[10] - Accounts receivable decreased to ¥382,526,668.11 from ¥391,761,721.40[10] - Inventory has decreased to ¥501,666,083.77 from ¥697,614,358.66[10] Audit Status - The report was not audited, indicating that the figures presented are preliminary and subject to change[18]

证券代码：002432 证券简称：九安医疗 公告编号：2023-023 天津九安医疗电子股份有限公司关于举行 2022年度及2023年第一季度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）2022 年年度报告、 2023 年 第 一 季 度 报 告 定 于 2023 年 4 月 29 日 披 露 于 巨 潮 资 讯 网 （www.cninfo.com.cn），为了让广大投资者能进一步了解公司 2022 年年度、2023 年第一季度的经营情况，公司将于 2023 年 5 月 5 日下午 15:00-16:30 在同花顺 举行 2022 年度及 2023 年第一季度网上业绩说明会。本次业绩说明会将采用网络 远程文字交流的方式举行，本次年度报告说明会将采用网络远程方式举行，投资 者可登陆同顺路演平台（https://board.10jqka.com.cn/ir）或者同花顺 App 端入口（同花顺 App 首页-搜索-路演平台）参与本次说明会。 出席本次说明会的人员有：公司董事长兼 ...